Treating Waldenström Macroglobulinemia

Waldenström macroglobulinemia (WM) is the rare blood cancer that somehow manages to be both slow-moving
and dramatic. Slow-moving, because many people don’t need treatment right away. Dramatic, because WM can
make your blood extra “thick” with a protein called IgMthink maple syrup vibes, but in a situation where syrup
is not the goal.

The good news: there are more effective WM treatment options than ever, including targeted therapies (like BTK
inhibitors), chemoimmunotherapy combinations, and rapid “pressure release” procedures for emergencies. The better
news: treatment is usually personalized, so you and your specialist can match the plan to your symptoms, your lab
results, your lifestyle, and your tolerance for medical appointments that start at 7:00 a.m. (why are they always
at 7:00 a.m.?).

This article explains the major ways WM is treated, why many people start with “watch and wait,” how doctors pick
a first therapy, and what living with treatment can look like in real life. (Quick note: this is educational
informationnot medical advice. Always use your oncology/hematology team as your main source of truth.)

WM in plain English: what’s actually happening?

WM is usually classified as a type of lymphoplasmacytic lymphoma (LPL). In WM, certain B cells grow out of
control and produce too much IgM antibody. That IgM can contribute to problems like anemia (low red blood cells),
fatigue, enlarged lymph nodes, neuropathy (tingling/numbness), andwhen IgM gets very highhyperviscosity syndrome
(blood that’s too viscous to flow normally).

Here’s the key mindset shift: WM is often indolent (slow-growing). That means “treat immediately”
is not the default. Instead, the goal is to treat when the disease is causing meaningful issues, and to avoid
unnecessary side effects when it isn’t.

When to start treatment: why “watch and wait” is often the first step

Many people with WM begin with active surveillance (also called “watchful waiting” or “watch and
wait”). This is not ignoring the diseaseit’s monitoring it closely and saving treatment for the moment it’s truly
needed. During surveillance, you’ll typically have regular clinic visits and blood work (often including IgM
levels, complete blood count, and sometimes other tests) to watch for changes.

Doctors generally recommend starting treatment when WM is causing symptoms or complications such as:

• Anemia or other low blood counts that cause symptoms (fatigue, shortness of breath, dizziness)
• Hyperviscosity symptoms (vision changes, headaches, bleeding issues, confusionurgent)
• Significant neuropathy linked to WM
• Symptomatic enlarged lymph nodes or spleen
• Kidney problems related to the disease
• “B symptoms” such as fevers, drenching night sweats, or unintentional weight loss
• Other IgM-related issues (for example, cold agglutinin disease or cryoglobulinemia in select cases)

Importantly, a high IgM level alone doesn’t always mean treatment must begin immediately. Many clinicians treat the
patientnot the numberunless there are warning signs of complications.

The WM treatment toolbox

WM treatment typically falls into a few big categories. Most plans combine strategies: controlling the IgM,
shrinking the lymphoma cells, and preventing or managing complications.

1) Plasmapheresis: the “IgM drain” for hyperviscosity

If WM causes hyperviscosity syndrome, doctors may use plasmapheresis (also called plasma
exchange). This procedure filters your blood to remove excess IgM in the plasma, then returns blood cells back to
you. It can lower IgM quickly and relieve symptoms fast.

A critical detail: plasmapheresis is often a bridge, not a permanent solution. It helps stabilize
someone in an urgent situation, but it doesn’t treat the underlying WM cells that keep producing IgM. That’s why
it’s commonly followed by systemic therapy (like targeted therapy or chemoimmunotherapy) to control the disease
longer-term.

Example: Someone arrives with blurry vision, nosebleeds, and an extremely elevated IgM. The team
may do plasmapheresis right away to reduce viscosity, then start disease-directed therapy once it’s safer.

2) Anti-CD20 immunotherapy and chemoimmunotherapy: classic, reliable options

Many WM regimens include rituximab, an antibody therapy that targets CD20 on B cells. Rituximab is
often combined with other drugs to deepen responses.

Common chemoimmunotherapy approaches your specialist may discuss include:

• Bendamustine + rituximab (BR) often used because it can produce strong, durable responses for
  many patients.
• Dexamethasone + rituximab + cyclophosphamide (DRC) sometimes favored for people who need a
  gentler regimen.
• Proteasome inhibitor–based combinations (often including bortezomib in some settings)
  effective, but neuropathy risk can matter a lot in WM.

One WM-specific wrinkle: rituximab can cause an IgM “flare” early in treatment (a temporary rise
in IgM). In someone at risk for hyperviscosity, clinicians may reduce that risk by timing rituximab carefully, using
plasmapheresis first, or starting with other medications before adding rituximab.

3) Targeted therapy: BTK inhibitors (and friends)

Over the last several years, targeted therapies have become central in WM care. The stars of this category are
BTK inhibitorsoral drugs that block a key signaling pathway used by WM cells to survive.

BTK inhibitors may be used alone or with other agents, depending on the situation. A commonly used BTK inhibitor is
zanubrutinib, and another important BTK inhibitor strategy is ibrutinib combined with
rituximab in certain contexts.

Why patients often like targeted therapy (when it’s appropriate):

• It’s oral (many people appreciate fewer infusion days).
• It can work well even when WM has returned after earlier treatments.
• It can be a strong option for patients who aren’t ideal candidates for chemo-based regimens.

Why targeted therapy still requires respect (and follow-up):

• Side effects can include low blood counts, bleeding/bruising tendency, infections, high blood pressure, or heart rhythm issues in some people.
• Drug interactions matter (your care team will want your full medication list, including supplements).
• Some BTK inhibitors are taken continuously, so long-term tolerability is part of the plan.

Newer strategies are also being studied in clinical trials, including combinations of targeted therapies (for
example, pairing BTK inhibitors with other agents). These are exciting, but trial participation is a personal
decisionand a great conversation to have with a WM specialist.

4) Stem cell transplant: for select situations

WM is usually managed without transplant, but autologous stem cell transplant (using your own
stem cells) may be considered for some people with relapsed disease, especially if they’re fit enough and the
disease has proven difficult to control with standard options.

Transplant is not a “one size fits all” answer. It can carry significant short-term risks, requires specialized
centers, and isn’t appropriate for many patientsparticularly those with certain comorbidities or frailty. Still,
it remains an option worth discussing in the right context.

5) Supportive care: not optional, not “extra”

WM care is more than anti-cancer therapy. Supportive care can make a major difference in how you feel and how well
you tolerate treatment:

• Treating anemia and fatigue (sometimes with transfusions, iron evaluation, or targeted WM control)
• Infection prevention (vaccines, prompt evaluation of fevers, and sometimes preventive meds depending on regimen)
• Neuropathy management (medication adjustments, physical therapy, pain management strategies)
• Bone health and general wellness (sleep, activity, nutritionyes, your body still counts as a body)

How doctors choose a first treatment: the “best” option depends on you

WM treatment decisions look less like a single highway and more like a GPS that keeps rerouting based on your
symptoms, lab results, and goals. Factors that often shape the plan include:

Symptoms and urgency

If hyperviscosity is present, lowering IgM quickly is the priorityoften with plasmapheresis. If anemia is the main
issue, a regimen that improves blood counts reliably may rise to the top.

Age, overall health, and “treatment intensity”

Some chemoimmunotherapy regimens can be more demanding physically. For a younger, fit patient, a time-limited
regimen may be appealing. For an older adult with multiple medical issues, an approach with a different risk
profile might make more sense.

Neuropathy and other IgM-related problems

If neuropathy is already a major symptom, clinicians often consider drug choices carefully to avoid making nerve
symptoms worse. Your baseline symptoms mattera lot.

Genetic markers (when available)

Many WM cases involve a mutation called MYD88, and some have CXCR4 mutations.
These markers can help specialists predict how the disease might behave and how it may respond to certain targeted
therapies. Not every decision hinges on geneticsbut when the information is available, it can be useful.

Your preferences (yes, they’re part of the science)

Some people strongly prefer a time-limited regimen (finish treatment, then monitor). Others prefer an oral therapy
that avoids infusion centers, even if it may be taken long-term. There isn’t one “correct” preferenceonly the one
that matches your situation and values.

Treating relapsed or refractory WM: what happens if it comes back?

WM can relapse, sometimes years after a successful first treatment. When it returns, your team will consider:

• How long your prior response lasted
• What side effects you experienced before
• Whether the relapse is slow and mild or fast and symptomatic
• Which drug classes you’ve already used (and what you haven’t)

In relapse, clinicians may reuse a prior regimen if it worked well and was tolerated, or switch to a different
class (for example, moving from chemoimmunotherapy to a BTK inhibitor strategy, or vice versa). Clinical trials can
be especially valuable here, because they may offer access to new combinations designed for previously treated
disease.

Side effects and safety: what to watch for (without spiraling)

Side effects vary widely depending on the treatment approach. The goal isn’t to “tough it out” silentlyit’s to
report symptoms early so your team can adjust, prevent complications, and keep you on track.

Common themes to discuss with your team

• Infection risk: Some therapies affect immune function. Ask about vaccines, timing, and when to call for fever.
• Bleeding or bruising: Especially relevant for some targeted therapies and for people on blood thinners.
• Heart and blood pressure: If you have a cardiac history, ask how your plan accounts for it.
• Neuropathy: Report tingling, numbness, or burning sensations earlydon’t wait for it to “prove itself.”
• Fatigue: Often improves as the disease comes under control, but may also reflect anemia, sleep changes, or stress.

Practical tip: keep a simple symptom note on your phone“what, when, how bad, what helps.” It turns your next
appointment into a strategy session instead of a memory quiz.

Questions to ask your WM specialist

• Do I need treatment now, or is watchful waiting safest?
• What is the main reason you’re recommending this regimen (anemia, IgM complications, lymph nodes, etc.)?
• Is hyperviscosity a concern for me? Do I need an eye exam or urgent precautions?
• Will we test for MYD88 and CXCR4, and how might results affect choices?
• Is this plan time-limited or ongoing? What would make us change course?
• What side effects should trigger a same-day call?
• Are clinical trials a good fit for me right now?

Real-life experiences: what “treating WM” can feel like (about )

Every WM story is unique, but many people recognize a few common chapters. Below are composite experiences inspired
by patterns patients frequently describeshared here to help you feel less alone and more prepared. (Details vary,
and none of this replaces medical guidance.)

Experience 1: “Watch and wait felt like watching a pot that never boils”

One person described diagnosis day as surreal: “I felt fine. I came in for routine labs. Suddenly I had a rare
lymphoma with a name that sounded like a spell from a fantasy novel.” Their doctor recommended surveillance. On
paper, it made senseno major symptoms, stable blood counts, and no urgent IgM complications. Emotionally, it was
harder. “Every follow-up appointment felt like getting a report card I didn’t study for.”

What helped was building a routine: regular labs on the same schedule, a list of symptoms to watch for, and a
standing agreement with the care team about what “starting treatment” would look like. Over time, the person said
the anxiety loosened its grip: “I learned that not treating was a deliberate medical choice, not neglect.”

Experience 2: “Plasmapheresis was the fastest ‘before and after’ I’ve ever lived”

Another patient recalled developing blurry vision and headaches, followed by a trip to the emergency department.
Testing showed hyperviscosity concerns. They underwent plasmapheresis and felt improvement quickly: “It was like
someone cleaned a foggy window.” The procedure itself was described as tiring but manageablemore weird than
painful, with lots of monitoring and a strong “you are definitely in a medical setting” vibe.

The key learning was that plasmapheresis solved the urgent problem, but it was not the whole plan. They started
disease-directed therapy afterward to keep IgM from building up again. “The procedure was the rescue boat. The
medication was learning how not to fall in the ocean again.”

Experience 3: “Treatment choices were about my life, not just my lymphoma”

A different patient emphasized the decision-making process. They worked full-time, cared for family, and wanted a
plan that fit reality. Their clinician reviewed optionsinfusion-based regimens versus oral targeted therapyand
discussed tradeoffs honestly: time in clinic, side effect profiles, and how quickly symptoms might improve. “The
best part was feeling like a partner in the plan.”

They also learned the power of early symptom reporting. Mild side effects that could have snowballed were handled
quickly with dose adjustments and supportive care. “I stopped trying to be the ‘easy patient.’ I became the ‘smart
patient’ who speaks up.”

Experience 4: “The emotional side was realand treatable”

Many people mention that WM treatment isn’t only physical. There’s the mental load: uncertainty, scan anxiety,
and the awkward moment when you realize you now know what IgM is (and you didn’t even take an immunology class).
Several patients report that counseling, support groups, mindfulness practices, or simply connecting with others
who have WM helped them reclaim a sense of control.

One person put it this way: “My goal wasn’t to be fearless. It was to be informed, supported, and stubbornly
hopeful.” That’s a pretty strong treatment plan for the human side of WM.

Conclusion: treating WM is a strategy, not a sprint

Treating Waldenström macroglobulinemia is about timing and tailoring. Many people start with watchful waiting,
begin therapy when symptoms or complications appear, and then move through treatment options over time as needed.
Your plan may include plasmapheresis for urgent hyperviscosity, rituximab-based combinations, BTK inhibitors, or
other approachesselected based on your goals and medical details.

If you take one thing from this article, let it be this: WM is treatable, and you have options. The best next step
is partnering with a hematologist/oncologist experienced in WM to build a plan that keeps you safe, functional, and
fully informed.